Abstract: To observe optical coherence tomography angiography (OCTA) images during follow-up of choroidal neovascularization (CNV) caused by pathological myopia (PM) or idiopathy and discuss OCTA's clinical applications Patients with CNV caused by PM or idiopathic CNV (ICNV) were recruited prospectively from the Department of Ophthalmology, West China Hospital from March 2015 to June 2015. Intravitreal injections of Ranibizumab were conducted on all patients and repeated treatments were performed based on examinations of follow-up. Patients received OCTA the first week after injection, together with measurements of best-corrected visual acuity (BCVA) and central macular thickness (CMT). Subsequent follow-up was done once a month.
INTRODUCTION

C
horoidal neovascularization (CNV) is a severe retinal and choroidal lesion resulting in vision loss or even blindness due to subretinal or intraretinal fluid, hemorrhage and ultimately the scar. 1, 2 The main cause of CNV is neovascular age-related macular degeneration (AMD), mainly affecting elder patients. 1, 3 Pathological myopia (PM) occupies the majority proportion of non-AMD CNV with the rate of 5% to 11% among its population. 1 Other less common sources include angioid streaks, multifocal choroiditis, punctate inner choroidopathy, presumed ocular histoplasmosis syndrome, and trauma. [1] [2] [3] [4] Idiopathic CNV (ICNV) is defined as CNV without obvious signs of above reasons, influencing about 17% of CNV patients. 5 Although these CNVs show a relative more favorable natural course than AMD sourced, 5 permanent visual impairment and repeated recurrences might occur, from which patients suffer for a life time. Intravitreal injection of antivascular endothelial growth factor (VEGF) agents has been proved to be effective and safe in recent years for a variety of CNV.
Fluorescein fundus angiography (FFA) is the gold criteria of CNV with the dye distributing in retinal vessels directly. Nevertheless, rare side-effects such as nausea and even anaphylaxis limit the application of FFA and it is relatively contradicted on patients with heart or renal dysfunction. Furthermore, FFA is time-consuming especially in rushed hospitals, bringing about inconvenience on both doctors and patients to some extent.
The newly developed optical coherence tomography angiography (OCTA) could cover some of deficiencies of FFA through its noninvasive and rapid process. OCTA provides the imaging of en-face retinal and choroidal vasculature by detecting erythrocytes flowing in blood vessels with time. 6 The meantime OCT Bscan demonstrates direct comparisons between the structure and angiograms on the same cross-section. Split-spectrum amplitude decorrelation angiography (SSADA) algorithm was applied to improve the signal-to-noise for faster acquisition time and better images. 7, 8 Motion correction was used by conducting two orthogonal imaging to adjust patients' movements. 7, 9 In this study, we visualized the PM and idiopathic sourced CNV changes qualitatively by OCTA during patients' follow-up. (2) . Patients were treatmentnaïve or had recurrent CNV with the last treatment 6 months before. Exclusion criteria were: (1) . opaque refractive medium interfering imaging such as severe cataract or vitreous hemorrhage, (2) . large amount of fundus hemorrhage caused by CNV preventing the incidence light from penetrating the retina.
MATERIALS AND METHODS
Study Design
Patients undertook a thorough ophthalmic examination at baseline including best-corrected visual acuity (BCVA) test, intraocular pressure measurement, dilated fundus examination by indirect ophthalmoscope and color fundus photography. BCVA was converted to logarithm of minimal angle resolution (logMAR). All CNV was confirmed by FFA. A single intravitreal injection of Ranibizumab (Lucentis; Genentech, Inc, South San Francisco, CA) was conducted on all patients. Extra treatments would be added if persistent hemorrhage or increase of the fluid was detected during follow-up.
Optical Coherence Tomography Angiography
OCTA was conducted by RTVue XR Avanti with AngioVue (Optovue Inc.,Fremont, CA) at 70,000 A-scans per second containing 304 Â 304 A-scans in about 2.6 seconds. 3 Â 3-mm scanning area focused on the macular was acquired using SSADA technique and if the former showed no exact CNV or incomplete CNV borders, a 6 Â 6-mm scan was necessary for the entire CNV. Each of them consisted of two orthogonal images for motion correction. About 10-mm length B-scan and retinal map were achieved in the meantime to get the data of central macular thickness (CMT).
Outcomes and Follow-Up
Patients were followed up a week and a month after their injections, and then monthly follow-up was conducted subsequently. Main outcomes were BCVA and CMT. OCTA was repeated on them compared with changes of BCVA and CMT, combined with fundus photography and OCT B-scan.
Statistical Analysis
Statistical analysis was performed by SPSS (version 19.0 Inc., Chicago). Changes of BCVA and OCT were compared with baseline using Wilcoxon test. P values less than 0.05 were regarded as statistically significant.
RESULTS
Baseline Characteristics
General characteristics of patients were listed in Table 1 . About 10 eyes from 10 patients were included in this study and mean age was (46.20 AE 10.15) years old. Around 6 (60%) of them were females and the other 4 (40%) were males. Also 5 (50%) were diagnosed with PM and 5 (50%) were ICNV and 2 (20%) patients had obvious intraretinal fluid and 4 (40%) had subretinal fluid. Mean follow-up was (7.82 AE 2.47) weeks. Except 4 (40%) patients got only 1 injection, 5 (50%) received two injections and 1 (10%) patient got 4 (once every two weeks) due to his treatment-resistant lesion. Around 2 (20%) of 10 patients had CNV recurred and both received intravitreal Ranibizumab more than half a year ago. Mean injections of this study was 1.80 AE 0.92. Detailed information of these 10 patients was demonstrated in Table 2 with their data of BCVA and CMT.
Changes or Best-Corrected Visual Acuity and Central Macular Thickness Table 3 gave BCVA of included patients in each follow-up. Mean baseline BCVA of 10 patients was (0.81 AE 0.45) logMAR. After treatments, it improved to (0.68 AE 0.43) significantly (P ¼ 0.028) at 1 week and (0.51 AE 0.40) at 1 month (P ¼ 0.005). BCVA became (0.50 AE 0.40) at last followup, indicating significant increase ((P ¼ 0.005). Follow-up data of CMT was shown in Table 4 . CMT of baseline was (276.90 AE 69.73) um. It decreased to (254.60 AE 58.31) um and (257.4 AE 62.14) um at 1 week and 1 month, respectively. The result showed significant difference at 1-week follow-up (P ¼ 0.006), turning out to be not statistically significant at 1 month compared to baseline (P ¼ 0.037). At final visit, CMT declined to (249.70 AE 53.37) um, which was statistically significant (P ¼ 0.008).
TWO SELECTED CASE REPORTS Case Report 1
A 52-year-old female complaint of vision loss and metamorphopsia of her right eye. She was diagnosed with CNV caused by PM in her right eye. At baseline, she had a BCVA of 0.6 logMAR and CMT of 334 um. OCT B-scan, OCTA, fundus photography, and FFA were conducted on her affected right eye before treatment (Figure 1 ). She received intravitreal injection of Ranibizumab (0.5 mg/0.05 ml). A week later, BCVA was 0.3logMAR and CMT reduced to 276 um. OCTA demonstrated obvious reduction of the size and vessel density; however, the feeder blood remained almost unchanged. 1 month later, her BCVA returned to 0.4 and CMT increased to 359 um. OCTA showed reoccurrence of CNV, remarkable intraretinal fluid accumulated according to correlated B-scan and hemorrhagic persisted on fundus photography and. Then she received a OCTA showed a reduction of CNV in size and vessel density compared to baseline. All follow-up images were presented in Figure 2 . Additional treatments may be necessary for her if hemorrhagic recurs or expanding of the CNV indicated by OCTA.
Case Report 2
A 47-year-old male patient was diagnosed with ICNV in his right eye 2 years ago and had his lesion stable after treated by intravitreal injection of Ranibizumab. Around 3 months ago, his vision deteriorated rapidly and BCVA was only 1.39 logMAR. FFA and OCTA revealed recurrence of ICNV on his right eye ( Figure 3 ) and CMT was 346 um based on OCT B-scan. Considering his long course of disease and severe condition, he received injections of Ranibizumab every two weeks with a double dose (1.0 mg). At a week after his first injection, his BCVA was stable and CMT reduced to 302 um. After two injections (1 month later), BCVA recovered slightly to 1.00 and CMT was 297 um. OCTA showed improvement of CNV compared with baseline image. Then another two injections were performed on his right eye biweekly. At week 6 and 8, OCTA remained almost unchanged and no obvious hemorrhage was found on fundus photography. BCVA was finally 1.00 logMAR and CMT was 282 um. All follow-up images were presented in Figure 4 .
DISCUSSION
We conducted a prospective case series to explore the efficacy of OCTA imaging on CNV patients' follow-up. As OCTA has been applied in some institutions, several studies were carried out to research the value of OCTA in a variety of ocular diseases, most of which were cross-sectional studies or case reports. To the best of our knowledge, several studies have reported OCTA images of CNV arising from neovascular AMD, but CNV related to PM or idiopathic was seldom observed.
FFA is still the primary examination when patients are suspected with CNV by showing the form and function of CNV directly with dye flow and leakage. Traditional OCT-B scan demonstrates the structure of retinal and choroidal layers, mainly observing hemorrhage and fluid with different signal strengths; however, authentic images of CNV could not be revealed and tended to be confused with similar tissues, for example, the drusen. 9, 10 In consideration of some side-effects such as nausea, vomiting and even anaphylaxis caused by contrast agents and limitations of structural OCT, the advanced OCTA compensates part of their shortage and provides vessels' arrangement of CNV through the technique SSADA, which distinguishes CNV with other structures by detecting flowing red blood cells.
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This study combined OCTA images with some quantitative parameters such as BCVA and CMT at each follow-up. In total, the reduced of size and vessel density of CNV accompanied increase of BCVA and decrease of CMT. Correlated OCT-B scan showed the relief of intraretinal or subretinal fluid and hemorrhage was absorbed when observing dilated fundus. Nevertheless, only 4 of 10 patients had their CNV stable after first treatment. Around 5 received two injections and 1 patient got 4 injections (once every two weeks) due to his resistant lesion. Among recurrent patients, improvement of BCVA and CMT could be found and OCT-B scan implied lessen of hemorrhage and edema. OCTA detected the persistent central trunk of CNV in spite of the reduction of its size. Similar images were reached by Kuehlewein et al 7, 12 with unchanged feeder vessels. Previous studies speculated that these feeder vessels were hard to be eliminated by anti-VEGF agents on account of the protection from pericytes, while endothelial cells of other vessels were exposed to targeting drugs. 13 This point was not observed by other equipments or examinations, manifesting some advantages of OCTA.
Images of OCTA were automatically divided into four layers: superficial, deep, outer retina, and choroid capillaries. As the outer retina appears to be short of blood supply in normal patients, additional neovascularization is typical and prominent under the avasular background.
14 In addition, CNV on the layer of choroid capillaries was surrounded by an area with insufficient blood vessels, contrary to normal patients with adequate capillaries. Because hypoxia and ischemia might be responsible for the happening of CNV, our findings could be explained by possible CNV pathogenesis. Coscas et al 15 has observed the loss of choriocapillaris of AMD patients in their study and raised some benefits of OCTA compared to time-consuming and invasive indocyanine green angiography.
The application of OCTA remained to be restricted to patients without rapid eye movements. 7, 9 Although motion correction was performed, frequent blink and shift of eyes led to difficulties for two orthogonal pictures merging into an intact one. 16 Images of incoordinate patients turned out to be distorted and no value for guidance and reference. Moreover, great amount of hemorrhage prevented the beam from penetrating through the retina, covering the existence of CNV and brought about challenges when finding the source of hemorrhage. de Carlo et al 6 conducted a diagnostic test to judge the efficacy of OCTA, with the sensitivity of 50% and specificity 91%. Around 3 of their false-negative cases were because of subretinal hemorrhage. In this study, we excluded these patients to achieve better and more precise images without disturbance of blood leakage. For PM patients, we faced several difficulties when we captured images from them, which are necessary to be specified. First, many lesions could be observed on PM's ocular fundus, such as lacquer cracks, RPE atrophy, and retinoschisis, which may disturb the appearance of CNV. Second, patients with severe RPE atrophy bare a poor fixation, having difficulty to cooperate our examinations. Third, the axial length of PM eye balls is relative long and impacts the accuracy of layer divided by OCTA automatically. These features of PM lead to increasing obstacles for both examiners and patients.
This study has several limitations. First, only 10 patients were included in this study. Small sample size restricted the validity and feasibility of the conclusion to be applied. Second, the follow-up period was short and long-time efficacy of OCTA observing CNV changes after treatment remained ambiguous in this study. Trials with longer follow-up are necessary to confirm further practical effects of OCTA. Third, the OCTA had its internal limitations. Segmentation of retinal and choroid capillaries automatically was not precise and sometimes delineated the CNV together with upper or lower layers by mistake. 6 Software with the function of adjusting the CNV area manually or more accurate automatic delineating is demanded for clinical use. The largest range of observing the ocular fundus is 9 Â 9 mm and locates mainly on the posterior pole. Images of peripheral fundus are hard to be gained and it is quite impossible for patients to move their eyes because a stable fixation point is necessary for two orthogonal scans. Images with high quality are hard to acquire if patients are unable to maintain their eyes and heads' position. Eye movement is the main problem in the process of obtaining satisfactory pictures. Therefore, the technique with faster scanning speed and larger observing size is desirable in subsequent research.
In conclusion, OCTA presented the detailed CNV form with the technique SSADA and had advantages of rapid, noninvasive and repeatable. Images of OCTA were almost consistent with increase of BCVA and decrease of CMT. Besides, additional information which might not be found by other examinations could be provided based on OCTA, such as the size and vessel density of CNV. OCTA shows a promising future in clinical application. Further studies with larger sample size and longer follow-up are necessary to explore the value of OCTA and more advanced OCTA is being expected to compensate for current shortages. 
